Abstract:Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene. Premature termination codons (PTCs) represent ∼9% of CF mutations that typically cause severe expression defects of the CFTR anion channel. Despite the prevalence of PTCs as the underlying cause of genetic diseases, understanding the therapeutic susceptibilities of their molecular defects, both at the transcript and protein levels remains partially elucidated. Given that the molecular pathologies depend on the PTC positions in CF, multiple pharmacological interventions are required to suppress the accelerated nonsense-mediated mRNA decay (NMD), to correct the CFTR conformational defect caused by misincorporated amino acids, and to enhance the inefficient stop codon readthrough. The G418-induced readthrough outcome was previously investigated only in reporter models that mimic the impact of the local sequence context on PTC mutations in CFTR. To identify the misincorporated amino acids and their ratios for PTCs in the context of full-length CFTR readthrough, we developed an affinity purification (AP)-tandem mass spectrometry (AP-MS/MS) pipeline. We confirmed the incorporation of Cys, Arg, and Trp residues at the UGA stop codons of G542X, R1162X, and S1196X in CFTR. Notably, we observed that the Cys and Arg incorporation was favored over that of Trp into these CFTR PTCs, suggesting that the transcript sequence beyond the proximity of PTCs and/or other factors can impact the amino acid incorporation and full-length CFTR functional expression. Additionally, establishing the misincorporated amino acid ratios in the readthrough CFTR PTCs aided in maximizing the functional rescue efficiency of PTCs by optimizing CFTR modulator combinations. Collectively, our findings contribute to the understanding of molecular defects underlying various CFTR nonsense mutations and provide a foundation to refine mutation-dependent therapeutic strategies for various CF-causing nonsense mutations.

Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development

Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression

Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons

The Functional Mechanisms and Clinical Application of Read-Through Drugs.

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

Therapeutic Suppression of Nonsense Mutation: an Emerging Target in Multiple Diseases and Thrombotic Disorders

Translation termination codons in protein synthesis and disease

Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases

Stop Codon Context-Specific Induction of Translational Readthrough

Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches

Guanidino Quinazolines and Pyrimidines Promote Readthrough of Premature Termination Codons in Cells with Native Nonsense Mutations

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion

PTC124 Targets Genetic Disorders Caused by Nonsense Mutations.

Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms

Extended stop codon context predicts nonsense codon readthrough efficiency in human cells

Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3

Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations

The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy

TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR

Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations

Premature Termination Codon Readthrough In Drosophila Varies In A Developmental And Tissue-Specific Manner